Alan Barrett, PA
Medical · Florence, SCNPI 1922174119
Payments from drug & device makers
Across 199 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$973
- Novo Nordisk$607
- GSK$229
- Amgen$144
- Dexcom, Inc.$114
- Lilly USA, LLC$105
- plus $882 from 24 others
What the payments were for
- Food & beverage$3,02399%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $973 |
| Novo Nordisk | 42 | $607 |
| GSK | 14 | $229 |
| Amgen | 9 | $144 |
| Dexcom, Inc. | 6 | $114 |
| Lilly USA, LLC | 7 | $105 |
| Novartis | 6 | $97 |
| Boehringer Ingelheim | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $67 |
| AstraZeneca | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Pfizer | 3 | $45 |
| Merck | 3 | $45 |
| Stryker | 1 | $44 |
| Johnson & Johnson | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Renalytix AI, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$3,055 in reported general payments places this provider in the 75th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 161 | $190,594 |
| OzempicSemaglutide | 103 | $119,821 |
| MounjaroTirzepatide | 82 | $113,146 |
| RybelsusSemaglutide | 57 | $96,868 |
| EliquisApixaban | 91 | $88,294 |
| TrulicityDulaglutide | 29 | $53,016 |
| LinzessLinaclotide | 61 | $49,199 |
| FarxigaDapagliflozin Propanediol | 36 | $45,552 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $37,768 |
| EntrestoSacubitril/Valsartan | 22 | $37,642 |
| TradjentaLinagliptin | 33 | $29,581 |
| XareltoRivaroxaban | 34 | $27,855 |
| MovantikNaloxegol Oxalate | 60 | $27,706 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $26,191 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $25,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Combivent Respimat | $76 | $256,874237 claims |
| Novo NordiskOzempic, Rybelsus | $607 | $216,689160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $105 | $166,162111 claims |
| PfizerEliquis | $45 | $88,29491 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $60 | $64,22883 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $229 | $51,00464 claims |
| AbbVieLinzess | $973 | $49,19961 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $45 | $41,22447 claims |
| NovartisEntresto | $97 | $37,64222 claims |
| Johnson & JohnsonXarelto | $39 | $27,85534 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $20,88620 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $75 | $6,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 medical providers in South Carolina.
Other medical in Florence
- Charlotte HannaFlorence$5K
- Whitney SimsFlorence$4K
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.